Share Twitter LinkedIn Facebook Email Eunice Wang, MD, talks about some of the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who have failed prior TKI therapy at the 2018 Annual Meeting.
Molecular Changes and Patient Stratification – Parrish Phimes, MD Acute Myelogenous Leukemia 2 Mins Read
Inequities in AML Outcomes: Comprehensive Discussion by Pramilla Krishnamurthy Acute Myelogenous Leukemia 2 Mins Read